Esperion
FDA greenlights first oral, daily, non-statin therapy for lowering LDL-Cholesterol
February 25, 2020Manufacturing and Production, Sales and Marketing Esperion, FDA, Nexletol, pharma
Esperion’s ATP Citrase Lyase (ACL) inhibitor Nexletol (bempedoic acid) has secured approval from the FDA, it has emerged. It is …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
